Surprise strong showing for Galapagos' JAK1 inhibitor in rheumatoid arthritis
This article was originally published in Scrip
Executive Summary
Galapagos has reported unexpectedly strong Phase II data with its JAK1 inhibitor GLPG0634 in rheumatoid arthritis (RA). The company has yet to decide whether or not to partner the product, but said its 2011 financial guidance "will only be achievable in the event the GLPG0634 programme is successfully partnered before year end".